Miricorilant
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Miricorilant
- Molecular weight
- 428.45
- Structure (SMILES)
- O=c1[nH]c(=O)c(Cc2cccc(C(F)(F)F)c2)c([C@H]2CC[C@H](c3ccccc3)CC2)[nH]1
- cort 118335
- CORT-118335
- cort118335
- Cort118335
- CORT118335
- CORT118335 Oral
- miricorilant
- Miricorilant
- Miricorilant (Cohort A)
- Miricorilant (Cohort B)
- miricorilant [INN]
- MIRICORILANT [USAN]
- Miricorilant 10 mg
- Miricorilant 100 mg
- Miricorilant 150 mg
- Miricorilant 150 mg tablets
- Miricorilant 300 mg tablets
- Miricorilant 50 mg
- miricorilant inn
- miricorilant usan
- CAS registry numbers
- 1400902-13-7
- ChEMBL ID
- CHEMBL4297602
- InChIKey
- GVVUZBSCYAVFTI-IYARVYRRSA-N
- PubChem compound IDs
- 66550324
- FDA ingredient codes (UNII)
- 311Y5GV21M
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- miricorilant
- Type
- Synthetic organic
- Drug name stem
- -corilant
Mechanisms of action
- Action
- Antagonist
- Action type
- Antagonist
- Target
- Glucocorticoid receptor
- Gene symbol
- NR3C1
- Protein identifier
- P04150
- Median affinity
- 8.1
- Affinity units
- pKi
- Primary target
- Yes
- Condition
- Psychotic Disorders
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000677
- Subject identifier
- D011618
- Condition
- Weight Gain
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004566
- Subject identifier
- D015430
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001249
- Subject identifier
- D065626
- Condition
- Weight Gain
- Highest recorded phase
- 2
- Condition identifier
- HP:0004324
- Subject identifier
- D015430
- Condition
- Alcoholism
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007079
- Subject identifier
- D000437
- Condition
- Metabolic Diseases
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0019052
- Subject identifier
- D008659
- Condition identifier
- EFO_0000677
- Condition identifier
- EFO_0004566
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001249
- Highest recorded phase
- 2
- Condition identifier
- HP_0004324
- Condition identifier
- HP_0004324
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004985
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005084
- Condition identifier
- MONDO_0005090
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007027
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007079
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0019052
- NCT03818256
- NCT03823703
- NCT05117489
- NCT04466215
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 2
- Polar surface area
- 65.72
- Calculated partition coefficient (ALogP)
- 5.11
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 4
- Heavy atoms
- 31
- Molecular formula
- C24H23F3N2O2
- Natural product
- No
- Recorded assays
- 25
- Active assays
- 2
Active assay types
- Confirmatory
Related records
Trials (30)
- A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma
- A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
- A Study of Ponsegromab in People With Heart Failure
- A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
- A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
- A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus
- A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).
- Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants
- CPX-351 in Higher Risk Myelodysplastic Syndromes
- Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults
- Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
- Evaluating the Pharmacokinetics and Safety of Miricorilant
- Evaluation of Miricorilant on Liver Fat in Patients With MASLD
- First-in-human Study in Healthy Subjects
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
- Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
- Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
In development for (4)
- Alcohol dependence Phase 2
- Inborn errors of metabolism Phase 1
- Mental disorder Phase 1
- Metabolic dysfunction-associated steatohepatitis Phase 2